Ernest Mario
From 2003 until it was purchased by GlaxoSmithKline in 2007 he was chairman and CEO of Reliant Pharmaceuticals Inc. He was chairman and CEO of Alza Corp., which in 2001 was purchased by Johnson & Johnson, and previously held senior positions with Glaxo Holdings PLC, including CEO from 1989-1993 and deputy chairman from 1992-1993. He is a past chairman of the Ernest Mario School of Pharmacy at Rutgers University and is a director of Boston Scientific Corp., Celgene Corp., Maxygen Inc., and Vivus Inc.
- 2007 Third Quarter
Added to: Celgene Corp. - Summit, NJ
Celgene discovers and commercializes therapies to treat cancer and inflammatory diseases. Revenues are $13 billion.